Cambridge Investment Research Advisors, Inc. Regeneron Pharmaceuticals, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 5,344 shares of REGN stock, worth $3.61 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
5,344
Previous 5,181
3.15%
Holding current value
$3.61 Million
Previous $5.45 Million
3.16%
% of portfolio
0.02%
Previous 0.02%
Shares
30 transactions
Others Institutions Holding REGN
# of Institutions
1,497Shares Held
82.8MCall Options Held
1.22MPut Options Held
1.51M-
Vanguard Group Inc Valley Forge, PA9.32MShares$6.3 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$5.71 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.49MShares$5.06 Billion0.64% of portfolio
-
State Street Corp Boston, MA4.9MShares$3.31 Billion0.21% of portfolio
-
Capital World Investors Los Angeles, CA4.3MShares$2.9 Billion0.72% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $72.4B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...